Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palisade Bio (PALI) Equity Average (2016 - 2025)

Palisade Bio has reported Equity Average over the past 15 years, most recently at $66.3 million for Q4 2025.

  • Quarterly Equity Average rose 840.37% to $66.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.3 million through Dec 2025, up 840.37% year-over-year, with the annual reading at $68.4 million for FY2025, 627.85% up from the prior year.
  • Equity Average was $66.3 million for Q4 2025 at Palisade Bio, up from $2.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $66.3 million in Q4 2025 and troughed at -$18.3 million in Q1 2021.
  • The 5-year median for Equity Average is $7.7 million (2024), against an average of $8.6 million.
  • Year-over-year, Equity Average plummeted 97.54% in 2021 and then skyrocketed 840.37% in 2025.
  • A 5-year view of Equity Average shows it stood at $5.6 million in 2021, then skyrocketed by 120.73% to $12.5 million in 2022, then rose by 1.95% to $12.7 million in 2023, then plummeted by 44.48% to $7.0 million in 2024, then skyrocketed by 840.37% to $66.3 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Equity Average are $66.3 million (Q4 2025), $2.9 million (Q3 2025), and $4.0 million (Q2 2025).